老年人的主观记忆抱怨:多药和抗胆固醇负担的作用
Betül Gülsüm Yavuz Veizi1, Ekin Oktay Oğuz1, Mehmet Ilkin Naharci2
1Department of Geriatrics, Ankara Oncology Research and Training Hospital, Ankara, Turkey.
Journal of geriatric psychiatry and neurology
|May 1, 2025
概括
多药性和高抗胆固醇负担与老年人的主观记忆抱怨有关. 减少药物复杂性和抗胆固醇药物暴露可能会改善认知健康.
科学领域:
- 老年学是指老年学的学科.
- 临床药房 临床药房
- 认知科学 认知科学
背景情况:
- 主观记忆问题 (SMC) 在老年人中很普遍,可能是认知能力下降风险的信号.
- 多药剂和抗胆固醇负担在SMC中的作用需要澄清.
- 这项研究考察了社区居住的老年人中药物使用和记忆障碍之间的关系.
研究的目的:
- 调查多药,抗胆固醇负担和SMC之间的关联.
- 为了确定老年人记忆障碍的危险因素.
主要方法:
- 从老年诊所接受的652名65岁以上的成年人的横截面研究.
- 通过临床医生管理的问题来评估SMC;通过MMSE来评估认知功能.
- 多药性定义为≥5种药物;按ABC尺度计算抗胆固醇负担.
主要成果:
- 48%的参与者报告SMC.
- 多药性 (OR=2.10) 和较高的抗胆固醇负担 (OR=2.39) 独立地与SMC相关.
- 慢性肺炎也是一个显著的预测因素 (OR=2.90).
结论:
- 多药和抗胆固醇负担是老年人中SMC的重要危险因素.
- 尽量减少药物复杂性和抗胆性暴露可能会减轻认知方面的投诉.
- 需要进一步的研究来确定因果关系和探索干预措施.
相关概念视频
01:22Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
01:26Alzheimer's Disease: Overview
315
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
315
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
85
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
85
01:24Parkinson's Disease: Treatment
148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148
01:28Drug Therapy
28
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
28
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
551
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
551